Retatrutide - The Triple Agonist

Why is Retatrutide not part of our Peptide/GLP-1 List:

1. It’s Still in Clinical Trials

Retatrutide is still in Phase 3 trials globally.

• Until those trials are completed,

• and safety + long-term data are confirmed,

  
  

  It cannot be approved by the TGA as it has not completed clinical trials globally

Australia doesn’t approve drugs early just because there’s hype — it follows full regulatory pathways.

2. TGA Approval Process Takes Time

Even after Phase 3:

• The sponsor (Eli Lilly) must submit to the TGA

• The TGA reviews:

• Safety

• Efficacy

• Quality manufacturing

• This can take 12–24+ months

So even in a best-case scenario, you’re looking at a delay after trials finish.

3. Safety Profile Still Under Review

Retatrutide is a triple agonist (GLP-1, GIP, glucagon) — more complex than Ozempic or Mounjaro.

That means regulators are watching closely for:

• Cardiovascular effects

• Metabolic impacts

• Long-term safety

• Adverse events at higher doses

The more potent the drug → the more scrutiny.

4. Pharmaceutical Strategy & Market Control

Even if approved globally:

• Pharma companies don’t always prioritise Australia first

• They often launch in:

• USA

• Europe

• Then expand later

Australia is a smaller market, so rollout can lag

5. Access Pathways in Australia Are Strict

Even before full approval:

• Access would likely be limited to:

• Clinical trials

• Special Access Scheme (SAS-B)

• And only under strict prescribing frameworks

6. Compounding & Legal Restrictions

This is important for your space:

• You cannot legally compound or supply unapproved substances freely

• The TGA is increasingly tightening control around:

• Peptides

• Weight loss injectables

• Off-label promotion

So even if there’s demand, it can’t just enter the market informally.

It has been stated that Retatrutide will never be available here in Australia legally because of our strict regulations.

It is NOT available anywhere globally in a legal framework at all - clinical trials will be completed in the United States at the end (maybe) of 2028 for countries like the USA & Europe first.

Why People Want Retatrutide

1. Significant Weight Loss Outcomes (Early Data)

In Phase 2 trials, participants achieved:

• ~20–24% average weight loss at higher doses over ~48 weeks

That’s:

• Comparable to (or exceeding) current GLP-1s like semaglutide

• Approaching outcomes seen with bariatric surgery in some cases

2. Triple Mechanism = Broader Metabolic Impact

Retatrutide is a triple agonist:

• GLP-1 → appetite suppression, slowed gastric emptying

• GIP → insulin regulation, metabolic effects

• Glucagon receptor → increases energy expenditure (fat burning)

That third pathway (glucagon) is what makes it different — it may:

• Increase calorie burn

• Improve fat metabolism

• Potentially enhance liver fat reduction

3. Potential Benefits Beyond Weight Loss

Early research suggests possible improvements in:

• Insulin sensitivity

• Type 2 diabetes markers

• Fatty liver disease (MASLD/NAFLD)

• Cardiometabolic risk factors

This positions it as a metabolic therapy, not just a weight loss drug.

4. Faster or More Profound Results

Some participants in trials:

• Continued losing weight beyond 1 year

• Had sustained reductions without plateauing early

That’s driving a lot of the hype.

Where It’s Being Trialed

Retatrutide is currently in global Phase 3 clinical trials.

Trial Locations Include:

• United States

• Europe (multiple countries)

• Asia

• Australia (select sites may be involved depending on the trial arm)

These are multinational, multicentre trials, which is standard for large pharmaceutical studies.

Who Is Running the Trials

Retatrutide is being developed and trialled by:

Eli Lilly and Company

• Same pharmaceutical company behind:

  • Mounjaro (tirzepatide)

  • Zepbound

They are one of the global leaders in:

• Diabetes

• Obesity

• Metabolic disease therapeutics

What Phase It’s In Now

• Completed: Phase 2 trials (very strong results)

• Current: Phase 3 trials (ongoing)

Phase 3 is the final stage before regulatory submission and involves:

• Larger populations

• Longer durations

• More detailed safety monitoring

Important Clinical Reality Check

There’s a reason for caution despite the hype:

• Long-term safety is still unknown

• Glucagon activation can have complex metabolic effects

• Higher potency = higher need for clinical oversight

• Dropout rates and tolerability still matter

WARNING

So if you buy it, it is definately black market, we can promise you that - be careful, you don't know where it is from, how it was made or what is in it!